πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

14,283 results for β€œB” Clear

  1. Olorofim

    Biotech Pharmaceutical Co.,

    Invasive Aspergillosis

    phase 3 small molecule active

    1 trial

  2. Olpasiran, Placebo for AMG 890

    Amgen

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  3. Olumiant 4 mg film-coated tablets, Placebo of Olumiant 4mg

    Pari Pharma GmbH

    Dermatomyositis; Baricitinib in patients with relapsing or naΓ―ve dermatomyositis.

    phase 3 small molecule active

    1 trial

  4. Olverembatinib

    Ascentage Pharma Group

    Ph+ ALL

    phase 3 small molecule active

    1 trial

  5. Omalizumab (Xolair)

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Urticaria

    phase 3 small molecule completed

    1 trial

  6. Omecamtiv Mecarbil, Omecamtiv Mecarbil, Matching Placebo, Omecamtiv Mecarbil

    Cytokinetics (Ireland) Limited

    Heart Failure With Reduced Ejection Fraction

    phase 3 small molecule active

    1 trial

  7. Omvoh 300 mg concentrate for solution for infusion, Omvoh 100 mg solution for injection in pre-filled syringe

    Eli Lilly Co.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  8. On-site bundled rapid HIV/HCV testing

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-related Disorders

    phase 3 other completed

    1 trial

  9. Once weekly subcutaneous injection of TransCon hGH

    Ascendis Pharma Endocrinology Division A/S

    Growth Hormone Deficiency, Pediatric

    phase 3 small molecule completed

    1 trial

  10. Ondansetron

    United Therapeutics Europe Ltd

    IBS - Irritable Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  11. Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer InfusionslΓΆsung, G

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  12. One4All

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 3 other completed

    1 trial

  13. Onpattro 2 mg/mL concentrate for solution for infusion., Sodium Chloride Intravenous Infusion BP 0.9% w/v

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  14. Ontamalimab

    Takeda

    Ulcerative Colitis

    phase 3 small molecule terminated

    3 trials

  15. Ontamalimab

    Takeda

    Crohn's Disease

    phase 3 mab terminated

    3 trials

  16. Ontamalimab

    Shire

    Crohn's Disease

    phase 3 small molecule terminated

    1 trial

  17. Opaganib

    RedHill Biopharma

    COVID-19

    phase 3 small molecule terminated

    2 trials

  18. Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease

    Chiesi Farmaceutici S.p.A

    Fabry disease (Ξ±-galactosidase A deficiency)

    phase 3 other active

    1 trial

  19. Open Label Topical Beremagene Geperpavec (B-VEC)

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab completed

    1 trial

  20. Open-label pitolisant

    Harmony Biosciences Holdings

    Idiopathic Hypersomnia

    phase 3 small molecule completed

    1 trial

  21. Open-label rusfertide

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  22. Opevesostat, FLUDROCORTISONE, PREDNISOLONE, DEXAMETHASONE ACETATE, HYDROCORTISONE, FLUDROCORTISONE ACETATE, ABIRATERONE ACETATE, DEXAMETHASONE, ABIRATERONE ACETATE, HYDROCORTISONE, HYDROCORTISONE, ENZALUTAMIDE, HYDROCORTISONE, PREDNISONE, PREDNISONE ACETATE, HYDROCORTISONE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  23. OraVescent Fentanyl

    Teva Pharma GmbH

    Low Back Pain

    phase 3 small molecule completed

    1 trial

  24. OraVescent Fentanyl

    Teva Pharma GmbH

    Pain

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources